STRATOSPHERE
Research type
Research Study
Full title
The STRATOSPHERE (STratification for RAtional Treatment-Oncomarker pairings of STAMPEDE Patients starting long-term Hormone treatment) Consortium Molecular Landscape Study
IRAS ID
244406
Contact name
Gerhardt Attard
Contact email
Sponsor organisation
University College London
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
The STAMPEDE trial cohort is a unique population of men with metastatic or locally advanced hormone sensitive prostate cancer, starting long-term androgen deprivation therapy (ADT), who have been randomised between a number of experimental treatments, including docetaxel or abiraterone, both now standard-of-care (SOC). The trial has demonstrated patients with metastatic or locally advanced hormone-sensitive prostate cancer receiving docetaxel or abiraterone treatments in addition to androgen deprivation therapy (ADT) have improved overall survival compared to men receiving ADT alone. There is now an urgent need to better understand at a molecular level this stage of the disease and develop tests that allow us to identify which patients stand to benefit the most from which treatment strategy.
A high proportion of patients participating in the STAMPEDE trial have given consent for excess tissue and/or plasma and/or blood to be used for research-based molecular studies.
In October 2017, the Prostate Cancer UK Scientific Committee recommended funding for a Precision Medicine Award to perform molecular analyses on tissue collected from patients recruited to STAMPEDE between 2005 and 2013. In December 2015, collection of saliva for germline analysis and sequential plasma samples commenced to enable us to track emerging resistance to treatment supported by a CRUK prospective sample-collection award.
We plan to use tissue and/or blood and/or saliva from patients participating within the STAMPEDE trial to identify a biomarker to stratify patients into subgroups based on prognosis and response to treatment.
REC name
London - Central Research Ethics Committee
REC reference
18/LO/1235
Date of REC Opinion
12 Jul 2018
REC opinion
Favourable Opinion